|
Free
Structural peptide demand favors Lilly, but peer data falls short of valuation proof.
|
Free
Strong beat and raised guidance meet rich multiples and heavy reinvestment cash drag.
|
Free
Oral GLP-1 and global filings signal a platform shift beyond injectable franchises.
|
Free
China's biotech rise and local manufacturing now define global GLP-1 competitive advantage.
|
Free
Tirzepatide's $12.8B quarter fuels upside but concentrates Lilly's revenue and risk exposure.
|
Free
Lilly leads on efficacy and oral reach, but Novo and pricing loom large.
|
Free
Tirzepatide powers two-thirds of revenue and global share gains, yet concentration risk persists.
|
Free
Foundayo's promising launch and pipeline advances are tempered by supply chain impurities that could require financial restatements.
|
Free
Analyzing the 55.5% revenue surge, capital allocation moves, and risks shaping the trillion-dollar pharma giant.
|
Free
A comprehensive assessment of clinical efficacy, manufacturing scalability, and PBM dynamics shaping the metabolic market.
|
Free
From tirzepatide's surgical-level weight loss to oral orforglipron, a story of systematic advantage.
|
Free
Comprehensive analysis of efficacy, safety, and commercial implications for obesity treatment market.
